1-3 of 3
Tim Welliver
Close
Sort by
Journal Articles

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Ola Landgren, MD PhD, Michel Attal, MD PhD, Dickran Kazandjian, MD, Murielle Roussel, MD, Jagoda K. Jasielec, MD, Dominik Dytfeld, Aparna Anderson, Tara Kervin, Karim Iskander, Khalid Mezzi, Tim Welliver, Akeem Yusuf, PhD BPharm, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1891.
https://doi.org/10.1182/blood-2019-127076
Published: 2019
Journal Articles

Could Patients with Multiple Myeloma (MM) Derive Additional Benefit from Their Treatments? Real-World Evidence for Carfilzomib Dosing Intensity on Survival and Treatment Progression

Rohan Medhekar, PhD, Dionne Hines, MPH, PhD, Sumeet Panjabi, PhD, Tim Welliver, MD PhD, Xin Wang, PhD, Rolin L. Wade, RPh, MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 836.
https://doi.org/10.1182/blood-2018-99-113414
Published: 2018
Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study

Ola Landgren, MD PhD, David S Siegel, MD PhD, Daniel Auclair, PhD, Ajai Chari, MD, Michael Boedigheimer, Tim Welliver, MD PhD, Khalid Mezzi, Karim Iskander, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 799.
https://doi.org/10.1182/blood-2018-99-112289
Published: 2018